← Cogent Biosciences, Inc. (COGT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cogent Biosciences, Inc. (COGT)
Pharmaceutical Preparations · market cap $5.4B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Cogent Biosciences (COGT) is a clinical-stage oncology-focused biotech with a $6.6B market cap and 205 employees, anchored by CGT9486 (combined with sunitinib) in Phase 3 for advanced gastrointestinal stromal tumors (GIST) and bezuclastinib in Phase 2 for advanced systemic mastocytosis (AdvSM). The company carries ~$241M cash but only ~8.3 months of runway at a ~$329M net loss rate in 2025, making near-term financing a live concern. No revenues have been recorded across the reporting period.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 2 · CGT4859imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| bezuclastinib | Phase 2 | Advanced Systemic Mastocytosis (AdvSM) |
| Bezuclastinib Tablets (Formulation A) | Phase 2 | SSM |
| CGT9486 plus sunitinib | Phase 3 | Advanced Gastrointestinal Stromal Tumors |
| CGT4859 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) |
| CGT9486 | Phase 3 | Gastrointestinal Stromal Tumors |
| Bezuclastinib in combination with sunitinib | Phase 2 | Gastrointestinal Stromal Tumors |
Price & technical context
3-month
-18.4%
6-month
-10.4%
12-month
+120.0%
52-wk range
$14.13–$42.84
vs 50-day MA
-12.8%
vs 200-day MA
-13.3%
Realized vol
91.1%
Max drawdown
-67.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for COGT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.